ETV5-mediated upregulation of IncRNA CTBP1-DT as a ceRNA facilitates HGSOC progression by regulating miR-188-5p/MAP3K3 axis

Ping Liu1,2,5, Ruiting Fu3,5, Kai Chen1,2,5, Lu Zhang1,2, Shasha Wang4, Weihua Liang1,2, Hong Zou1,2, Lin Tao1,2 and Wei Jia1,2✉

© The Author(s) 2021

High-grade serous ovarian cancer (HGSOC) is a common and lethal cancer of the female reproductive system. Long non-coding RNAs (lncRNAs) are aberrantly expressed in various cancers and play crucial roles in tumour progression. However, their function and molecular mechanism in HGSOC remain largely unknown. Based on public databases and bioinformatics analyses, the overexpression of IncRNA CTBP1-DT in HGSOC tissues was detected and validated in a cohort of HGSOC tissues. High expression of IncRNA CTBP1-DT was associated with poor prognosis and was an independent risk factor for survival. Overexpression of IncRNA CTBP1-DT promoted malignant biological behaviour of HGSOC cells, whereas its depletion induced growth arrest of HGSOC cells by vitro and in vivo assays. Mechanistically, IncRNA CTBP1-DT could competitively bind to miR-188-5p to protect MAP3K3 from degradation. Moreover, our results revealed that ETV5 could specifically interact with the promoter of IncRNA CTBP1-DT and activate its transcription. Collectively, these results reveal a novel ETV5/IncRNA CTBP1-DT/miR-188-5p/MAP3K3 pathway for HGSOC progression and suggest that IncRNA CTBP1-DT might be a potential biomarker and therapeutic target for HGSOC.

Cell Death and Disease (2021)12:1146 ; https://doi.org/10.1038/s41419-021-04256-9

INTRODUCTION

The global burden of ovarian cancer (OC) accounts for 2.5% of all malignancies among women [1]. It is the seventh most diagnosed cancer among women worldwide. In 2021, approximately 21,410 new diagnoses of OC and 13,770 OC deaths were expected to occur in the United States [2]. High-grade serous ovarian cancer (HGSOC) is the most common histological subtype of OC, accounting for 67.5% of OC subtypes [1, 3]. HGSOC is usually diagnosed at advanced stages due to the absence of characteristic symptoms at early stages [4]. It involves both ovaries and is characterised by aggressive behaviour and low survival. Despite the continuous improvement and development of surgical and systematic treatment, the mortality of OC patients has only decreased slightly. To date, the treatment of OC is still based on traditional surgery combined with chemotherapy. Under this treatment scheme, nearly 70% of patients experience relapse and chemotherapy drug resistance after treatment, and compared with other tumours, OC lacks effective molecular targeted therapy [3, 5]. Therefore, there is a pressing need to identify key molecular events underlying the progression and metastasis of HGSOC to improve diagnosis and prognosis.

Long non-coding RNAs (lncRNAs) are a set of non-protein-coding transcripts longer than 200 nucleotides maintained at relatively low expression levels. They are involved in multiple biological processes, including post-transcriptional regulation, organisation of protein complexes, cell-cell signalling and allosteric regulation of proteins [6, 7]. LncRNAs play crucial roles in different carcinomas, including breast [8], colorectal [9], gastric [10] and renal [11] carcinoma. Furthermore, IncRNAs have been identified as novel biomarkers of many carcinomas [12, 13]. LncRNA CTBP1-DT, a newly identified IncRNA, regulates cervical cancer progression by sponging miR-3163 to upregulate ZNF217 [14], which could promote cell proliferation in hepatocellular carcinoma by regulating the miR-623/cyclin D1 axis [15]. However, the clinical significance and underlying biological mechanisms of IncRNA CTBP1-DT in the regulation of HGSOC have not been elucidated.

LncRNAs and mRNAs could interact by competing with microRNAs (miRNAs) [16, 17]. LncRNAs can also function as competing endogenous RNAs (ceRNAs) by competitively binding miRNAs, thereby modulating the de-repression of miRNA targets in the cytoplasm [18, 19]. For example, IncRNA PTAR, which may serve as a competing endogenous IncRNA by sponging miR-101, mediates the role of transforming growth factor β-induced epithelial-mesenchymal transition and the invasion-metastasis cascade of OC [20]. Thus, this provides new insight into the role of ncRNAs in tumours. Our previous study indicated that MAP3K3 was overexpressed and continuously activated nuclear factor

1NHC Key Laboratory of Prevention and Treatment of Central Asia High Incidence Diseases, First Affiliated Hospital, School of Medicine, Shihezi University/Department of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine, Shihezi, China. 2Department of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine, Shihezi, China. 3Department of Obstetrics and Gynecology, First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi, China. 4Department of Pathology, Binzhou Medical University Hospital, Binzhou, China. 5These authors contributed equally: Ping Liu, Ruiting Fu, Kai Chen. ✉email: jiawei@shzu.edu.cn

Received: 30 April 2021 Revised: 22 September 2021 Accepted: 4 October 2021
Published online: 09 December 2021
kappa B signalling in HGSOC; it is also an independent prognostic factor for patients with HGSOC [21, 22]. LncRNA CTBP1-DT, screened from The Cancer Genome Atlas (TCGA) database, was positively correlated with MAP3K3 expression. Whether lncRNA CTBP1-DT could regulate MAP3K3 to influence the biological behaviours of HGSOC cells is not clear.

In the present study, we discovered that lncRNA CTBP1-DT is significantly overexpressed in HGSOC tissues and is associated with poor prognosis of HGSOC patients. It functions as a key regulator by competitively binding to miR-188-5p to protect MAP3K3 from degradation and thus promotes the growth and progression of HGSOC both in vitro and in vivo. In addition, we observed that ETS variant transcription factor 5 (ETV5)-mediated transcription of lncRNA CTBP1-DT consequently facilitates the malignant biological behaviour of HGSOC cells. Our results provide novel insights into the progression and metastasis of HGSOC and a promising therapeutic target for HGSOC treatment.

RESULTS
LncRNA CTBP1-DT is highly expressed in HGSOC and correlates with poor prognosis
To investigate the role of lncRNA CTBP1-DT in human HGSOC, lncRNA CTBP1-DT expression was determined in 87 HGSOC tissues and 35 normal fallopian tube tissues; it was significantly overexpressed in HGSOC tissues than in normal fallopian tube tissues (Fig. 1A). LncRNA CTBP1-DT expression was relatively higher in ovarian carcinoma cell lines (SKOV3, A2780, C13*, OV2008, HeyA8 and OVCA433), oesophageal carcinoma cells (109), angiosarcoma cells (ISO) and renal clear cell carcinoma cells (786–O) was detected by qRT-PCR. C, D Kaplan–Meier plots were used to determine the association between the lncRNA CTBP1-DT expression level and the OS/DFS of patients with HGSOC. E, F Log-rank test was used to determine the association between lncRNA CTBP1-DT expression level and the survival times in patients with HGSOC in the TCGA HGSOC datasets. Data are presented as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
OV2008, HeyA8 and OVCA433) than in oesophageal carcinoma cells (109), angiosarcoma cells (ISO) and clear cell renal cell carcinoma cells (786–0) (Fig. 1B).

The correlation of IncRNA CTBP1-DT expression with clinicopathological factors in HGSOC patients is summarised in Table 1. IncRNA CTBP1-DT overexpression was significantly associated with FIGO stage ($P = 0.044$), age ($P = 0.006$) and chemotherapeutical response ($P = 0.027$). Survival information of the registered 76 patients was gathered, and overall survival (OS) and disease-free survival (DFS) curves were obtained using the Kaplan–Meier assay. Patients with IncRNA CTBP1-DT overexpression had significantly shorter OS and DFS rates ($P < 0.05$, Fig. 1C, D). Similarly, higher IncRNA CTBP1-DT expression correlated with significantly shorter OS and DFS in the TCGA HGSOC dataset ($P < 0.05$, Fig. 1E, F).

Moreover, univariate analysis of the Cox regression model indicated that expression of IncRNA CTBP1-DT ($P = 0.048$), age ($P = 0.048$) and FIGO stage ($P = 0.006$) might be the prognostic factors for patients with HGSOC. Multivariate analysis showed that FIGO stage was an independent risk factor for HGSOC (Table 2). These results indicated that IncRNA CTBP1-DT expression was positively associated with poor prognosis of HGSOC patients.

### Table 1. The correlation of IncRNA CTBP1-DT expression with clinicopathological factors of HGSOC patients.

| Characteristics | n  | CTBP1-DT expression | $\chi^2$ | P value |
|-----------------|----|---------------------|---------|---------|
|                 |    | Overexpression (%)  | Low expression (%) |
| Age             |     |                     |          |         |
| <55             | 44  | 20 (45.5)           | 24 (54.5) | 7.587   | 0.006** |
| ≥55             | 43  | 32 (74.4)           | 11 (25.6) |          |         |
| FIGO stage      |     |                     |          |         |
| I–II            | 21  | 12 (57.1)           | 9 (42.9)  | 4.066   | 0.044*  |
| III–IV          | 66  | 40 (60.6)           | 26 (39.4) |          |         |
| Chemotherapy response | |                   |          |         |
| Sensitive       | 34  | 15 (44.1)           | 19 (55.9) | 4.870   | 0.027*  |
| Partial         | 34  | 24 (70.6)           | 10 (29.4) |          |         |
| Unknown         | 19  |                     |          |         |
| Ascites         |     |                     |          |         |
| No              | 26  | 16 (61.5)           | 10 (38.5) | 0.048   | 0.826   |
| Yes             | 61  | 36 (59.0)           | 25 (41.0) |          |         |

$\chi^2$ test.

LncRNA CTBP1-DT overexpression was significantly associated with age ($P = 0.006$), FIGO stage ($P = 0.044$) and chemotherapy response ($P = 0.027$) by $\chi^2$ test. *$P < 0.05$, **$P < 0.01$.

LncRNA CTBP1-DT promotes HGSOC cell proliferation, migration and invasion in vivo and in vitro

The functional effects of IncRNA CTBP1-DT in HGSOC were explored. Functionally, the cell proliferation assay demonstrated that knockdown of IncRNA CTBP1-DT significantly decreased cell proliferation in SKOV3 cells, whereas overexpression of IncRNA CTBP1-DT significantly increased cell proliferation in OV2008 cells (Fig. 2A, B). We further investigated the role of IncRNA CTBP1-DT in the motility of HGSOC cells. As shown in Fig. 2C, the transfection of IncRNA CTBP1-DT with short hairpin RNA (shRNA) impeded the migratory ability of SKOV3 cells. A corresponding effect on invasiveness was also observed in a parallel invasion assay. Conversely, transfection of OV2008 cells with the IncRNA CTBP1-DT vector promoted cell migration and invasiveness (Fig. 2D). These results indicate that IncRNA CTBP1-DT has oncogenic properties that can promote the migratory and invasive phenotype in HGSOC cells.

To clarify the effects of IncRNA CTBP1-DT on tumour growth in vivo, SKOV3 cells with stable IncRNA CTBP1-DT shRNA were subcutaneously injected into nude mice (Fig. 2E). In vivo optical imaging with bioluminescence and fluorescence was performed to detect the metastatic effect of sh-IncRNA CTBP1-DT in vivo. Unfortunately, we did not find any metastatic nodules of the transplanted tumours (Fig. 2F). Even after autopsy, non-metastatic nodules were found in the abdominal cavity, greater omentum, liver, lung and other organs. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) assays showed that the expression of IncRNA CTBP1-DT was markedly decreased in xenograft tumours from the sh-IncRNA CTBP1-DT mice (Fig. 2G).

Consistent with the in vitro results, low expression of IncRNA CTBP1-DT significantly reduced the tumour volume and weight compared with those in the control group (Fig. 2H–J).

LncRNA CTBP1-DT promotes the malignant biological behaviour of HGSOC cells by upregulating MAP3K3

To clarify the mechanism and biological function of IncRNA CTBP1-DT in HGSOC cells, bioinformatics analysis revealed that overexpression of IncRNA CTBP1-DT corresponded with overexpression of MAP3K3 in HGSOC. Moreover, we verified the correlation between MAP3K3 and IncRNA CTBP1-DT. The abundance of MAP3K3 mRNA and protein in SKOV3 cells with endogenous overexpression of MAP3K3 decreased after knockdown of IncRNA CTBP1-DT (Fig. 3A, C). Conversely, the transfection of IncRNA CTBP1-DT enhanced the abundance of MAP3K3 in OV2008 cells (Fig. 3B, D).

Knockdown of IncRNA CTBP1-DT in SKOV3 cells inhibited cell proliferation, migration and invasion, which could be reversed by overexpression of MAP3K3 (Fig. 3E, G, H, K, L). In contrast, overexpression of IncRNA CTBP1-DT promoted proliferation, migration and invasion of OV2008 cells, which could be reversed by knockdown of MAP3K3 (Fig. 3F, I, J, M, N). Collectively, IncRNA CTBP1-DT could promote the malignant biological behaviour of HGSOC cells by upregulating the expression of MAP3K3.

LncRNA CTBP1-DT serves as a miRNA sponge of miR-188-5p to regulate MAP3K3 expression in HGSOC cells

LncRNA CTBP1-DT was distributed in both the cytoplasm and nucleus of SKOV3 cells (Fig. 4A, B). We hypothesised that IncRNA CTBP1-DT in the cell cytoplasm might act as a miRNA sponge to prevent miRNAs from binding MAP3K3. Through bioinformatics analysis, miR-188-5p could bind both the IncRNA CTBP1-DT and MAP3K3 in similar seed regions (Fig. 4C). Through luciferase assay,
miR-188-5p inhibited the luciferase activities of the lncRNA CTBP1-DT wild-type binding motif, but there were no prominent differences in the mutant lncRNA CTBP1-DT (Fig. 4D). In addition, the luciferase activities of MAP3K3 wild-type binding sites were inhibited by miR-188-5p (Fig. 4E). These results indicated that miR-188-5p could interact with lncRNA CTBP1-DT and MAP3K3.

Subsequently, a binding RNA immunoprecipitation (RIP) assay was performed to validate their binding potential (Fig. 4F, G). The miR-188-5p inhibitor promoted lncRNA CTBP1-DT expression in OV2008 cells, whereas miR-188-5p mimics inhibited its expression in SKOV3. The expression of MAP3K3 corresponded with the expression of lncRNA CTBP1-DT (Fig. 4H, I). Consistent with these results, a binding RNA immunoprecipitation (RIP) assay was performed to validate their binding potential (Fig. 4F, G). The miR-188-5p inhibitor promoted lncRNA CTBP1-DT expression in OV2008 cells, whereas miR-188-5p mimics inhibited its expression in SKOV3. The expression of MAP3K3 corresponded with the expression of lncRNA CTBP1-DT (Fig. 4H, I).

### Table 2. Univariate and multivariate analyses of the associations between HGSOC patient risk factors.

| Risk Factor                      | Univariate HR (95% CI) | P value | Multivariate HR (95% CI) | P value |
|----------------------------------|------------------------|---------|--------------------------|---------|
| CTBP1-DT (low vs overexpression) | 2.155 (1.008–4.607)    | 0.048*  | 1.718 (0.796–3.710)      | 0.168   |
| Age (<55 vs ≥55)                 | 2.005 (1.008–3.988)    | 0.048*  | 1.983 (0.972–4.043)      | 0.060   |
| FIGO stage (I–II vs III–IV)      | 5.420 (1.615–18.186)   | 0.006** | 5.780 (1.663–20.089)     | 0.006** |
| Chemotherapy response (sensitive vs partial) | 0.887 (0.358–2.201) | 0.976   |
| Ascites (no vs yes)              | 1.247 (0.610–2.552)    |         | 1.247                    |         |

CI confidence interval, FIGO Federation International of Gynecology and Obstetrics, HR hazard ratio.

Expression of lncRNA CTBP1-DT (P = 0.048), age (P = 0.048) and FIGO stage (P = 0.006) might be the prognostic factors for patients with HGSOC by univariate analysis of the Cox regression model. FIGO stage (P = 0.006) was an independent risk factor for patients with HGSOC by multivariate analysis. *P < 0.05, **P < 0.01.

---

**Fig. 2** LncRNA CTBP1-DT promotes HGSOC cell proliferation, migration and invasion in vivo and in vitro. A, B CCK-8 assays were performed to determine the proliferation ability of SKOV3 cells transfected with sh-lncRNA CTBP1-DT or NC and OV2008 cells transfected with lncRNA CTBP1-DT or vector. C, D Transwell assays were performed in SKOV3 cells transfected with sh-lncRNA CTBP1-DT or control and OV2008 cells transfected with lncRNA CTBP1-DT or vector to explore cell migratory and invasive capabilities. E Image of mice in the lncRNA CTBP1-DT-knockdown and control groups. F Image of mice in the lncRNA CTBP1-DT-overexpression group and control group. G qRT-PCR was applied to determine lncRNA CTBP1-DT expression in tissues derived from the xenograft tumour model. H Image of subcutaneous tumour tissues in the lncRNA CTBP1-DT-overexpression group and control group. I Analysis of tumour volume of mice. J The relative weights of mouse tumours were measured. Data are reported as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
results, transfected miR-188-5p mimic reduced the expression of lncRNA CTBP1-DT in SKOV3 cells. Moreover, MAP3K3 expression was reversed by overexpression of lncRNA CTBP1-DT (Fig. 4J). Transfection of the miR-188-5p inhibitor resulted in the upregulation of lncRNA CTBP1-DT and upregulation of MAP3K3, which were reversed after knockdown of lncRNA CTBP1-DT in OV2008 (Fig. 4K). Overall, in HGSOC cells, lncRNA CTBP1-DT serves as a miRNA sponge of miR-188-5p to regulate MAP3K3 expression.

LncRNA CTBP1-DT is regulated by the transcription factor ETV5
To explore the mechanism of lncRNA CTBP1-DT upregulation in HGSOC, we applied the online bioinformatics software, JASPAR (http://jaspar.genereg.net/), to analyse transcription factors that could bind the promoter region of lncRNA CTBP1-DT. A total of eight potential transcription factors were found. Among them, ETV5 showed the highest correlation with lncRNA CTBP1-DT.
We designed shRNAs targeting ETV5. Expression of lncRNA CTBP1-DT was measured following ETV5 knockdown or overexpression. The results revealed that ETV5 knockdown led to a significant decrease in the expression of lncRNA CTBP1-DT in SKOV3 and A2780 cells. Moreover, ETV5 overexpression enhanced the expression of lncRNA CTBP1-DT in OV2008 cells. The expression of MAP3K3 corresponded with that of lncRNA CTBP1-DT (Fig. 5B–D). Consistent with these results, we found that the knockdown of ETV5-2 decreased the expression of lncRNA CTBP1-DT and MAP3K3 in SKOV3 and A2780 cells. However, these effects were reversed by overexpression of lncRNA CTBP1-DT.

Overexpression of ETV5 raised the expression of IncRNA CTBP1-DT and MAP3K3 in SKOV3 and A2780 cells. However, these effects were reversed by knockdown of IncRNA CTBP1-DT (Fig. 5E–G).

To confirm that IncRNA CTBP1-DT was the transcriptional target of ETV5, we constructed three different deletion fragments of IncRNA CTBP1-DT, which were cloned into vectors (Fig. 5H). Luciferase activity was measured after transfection of these fragments of IncRNA CTBP1-DT into HEK 293T cells. Figure 5I shows that there was no statistically significant difference in luciferase activity between the full-length plasmid and the deletion constructs, indicating that 0–300-base pair (bp)
fragments contained regulatory elements, which were critical for the transcription of lncRNA CTBP1-DT. We introduced three points mutations, designated as pGL-300-mut1, pGL-300-mut 2 and pGL-300-mut3 (Fig. 5J). The three mutant plasmids were transfected into 293T cells, and luciferase assays were performed. Figure 5K shows that the pGL-300-mut1 vectors decreased promoter activity compared to the wild-type control, indicating that the ETV5-binding site cluster is responsible for lncRNA CTBP1-DT transcription. A chromatin immunoprecipitation (ChIP) assay showed that approximately 16-fold enrichment of the promoter amplicons of lncRNA CTBP1-DT in the 0–300 bp binding sites in HGSOC cells was observed using the anti-ETV5 antibody (Fig. 5L), suggesting
that ETV5 could directly bind to the promoter of IncRNA CTBP1-DT.

Next, we determined whether the effect of ETV5 overexpression or knockdown on IncRNA CTBP1-DT affected the malignant biological behaviour of HGSOC cells. Knockdown of ETV5 significantly decreased cell proliferation over a 7-day culture in SKOV3 and A2780 cells, which was reversed after overexpression of IncRNA CTBP1-DT. Consistent with the proliferation outcomes, silencing ETV5 by shRNA also decreased the colony-forming ability of both cell lines (Fig. 6A, B). In addition, the transwell assay revealed a clear decline in migratory capacity of SKOV3 and A2780 cells transfected with sh-ETV5-2. Moreover, the invasion assay using SKOV3 and A2780 cells revealed that ETV5 markedly promoted cell invasion compared with the empty vector pcDNA3.1 transfection. This effect was abolished by IncRNA CTBP1-DT co-transfection (Fig. 6D, E). Proliferation, migration and invasion assays revealed that the overexpression of ETV5 enhanced the malignant biological behaviour of OV2008 cells, which was reversed after knockdown of IncRNA CTBP1-DT (Fig. 6C, F). These findings demonstrated that ETV5-induced HGSOC cell proliferation, migration and invasion might have been due to the transcription of IncRNA CTBP1-DT.

To investigate whether ETV5 could be associated with MAP3K3 expression level in HGSOC, the relationship between them in HGSOC tissue was visualised (Supplementary Fig. 1). The expression of ETV5 was highly positively correlated with MAP3K3, which made our study more comprehensive.

**DISCUSSION**

Our data demonstrated upregulation of IncRNA CTBP1-DT in HGSOC tissues compared to normal fallopian tube tissues and relatively higher expression in ovarian carcinoma cell lines than in other types of tumour cell lines, such as oesophageal carcinoma, angiosarcoma and clear cell renal cell carcinoma cell lines. Among 76 HGSOC patients, those with overexpressed IncRNA CTBP1-DT had significantly shorter OS and DFS rates. Similarly, higher expression of IncRNA CTBP1-DT was associated with significantly reduced OS in the TCGA HGSOC datasets, which is consistent with our experiments.

The biological function of IncRNA CTBP1-DT is rarely known. After detecting the relative expression of IncRNA CTBP1-DT by qRT-PCR, we found that IncRNA CTBP1-DT had high expression in SKOV3 and A2780 and low expression in OV2008. Consequently, SKOV3 and A2780 were selected to perform a loss-of-function assay, while OV2008 was chosen for gain-of-function assays. In this study, the proliferative, migratory and invasive capabilities of SKOV3 were significantly suppressed by the downregulation of IncRNA CTBP1-DT. Correspondingly, these features were remarkably enhanced by the upregulation of IncRNA CTBP1-DT in OV2008. Furthermore, tumour weight and volume were significantly reduced following the knockdown of IncRNA CTBP1-DT in orthotopic xenograft mouse models. In the present study, we did not observe metastasis of the subcutaneously transplanted tumour. However, Zhang et al. intraperitoneally injected HGSOC cells into nude mice to form peritoneal metastases, and metastatic lesions were found in the mesentery, omentum and liver [23]. We speculate that the different injection methods could explain the absence of metastatic lesions of the transplanted tumour in the present study. These findings support the potential pro-oncogenic function of IncRNA CTBP1-DT in HGSOC. Abundant evidence showed that abnormal expression of lncRNAs could lead to the development and progression of various tumours, including ovarian carcinoma. LncRNA HEIH has been found to accelerate cell proliferation and inhibit cell senescence in OC [24]. Moreover, IncRNA SNHG17, HOTTIP and DSCR8 are independent prognostic factors associated with recurrence in OC [25-27], suggesting that lncRNAs have considerable prognostic potential in OC.

In summary, MAP3K3 was regulated by IncRNA CTBP1-DT in HGSOC progression. In SKOV3, the abundance of MAP3K3 mRNA and protein decreased or increased after knockdown or overexpression of IncRNA CTBP1-DT, respectively. Knockdown of IncRNA CTBP1-DT in SKOV3 inhibited cell proliferation, migration and invasion, which could be reversed by overexpression of MAP3K3. In addition, knockdown of MAP3K3 abrogated the effects of IncRNA CTBP1-DT overexpression in OV2008. These results indicate that MAP3K3 mediates the effect of IncRNA CTBP1-DT in regulating the malignant biological behaviour of HGSOC cells in vivo. Previous studies have confirmed that IncRNA USP2-AS1 [28], HOXD-AS1 [29] and HEIH [24] are upregulated in OC, which can, in effect, promote the progression and development of OC cells by upregulating the expression of downstream target genes. LncRNA CTBP1-DT has been shown to elevate ZNF217 expression in cervical cancer [14] and regulate phosphatase and tensin homologue to suppress OC cell proliferation [30]. Our study also showed that IncRNA CTBP1-DT could promote malignant biological behaviours of HGSOC cells by upregulating the expression of MAP3K3.

Previously, IncRNAs were thought to be biologically useless molecules arising from simple transcriptional ‘noise’ [31]. Emerging evidence reveals that IncRNAs participate in cellular biological and pathological processes. The function of IncRNAs is dependent on their subcellular localisation [32]. To further explore the regulatory molecular network of IncRNA CTBP1-DT with MAP3K3, cell cytoplasmic/nuclear fractionation and RNA fluorescence in situ hybridisation (FISH) assays suggested that IncRNA CTBP1-DT was preferentially localised in the cytoplasm. LncRNAs located in the cytoplasm could participate in gene regulation, including acting as a sponge of miRNAs to competitively bind to miRNAs and further relieve the suppression of miRNAs on their target genes [33]. Subsequently, though miRDB, Targetscan, miRtarBase and StarBase analysis, 14 miRNAs that can bind MAP3K3 were predicted. Based on data from the RNA22 and DIANA websites, miR-188-5p could bind both IncRNA CTBP1-DT and MAP3K3 in similar seed regions. This was confirmed by luciferase reporter and RIP assays, which demonstrated that miR-188-5p could directly bind to IncRNA CTBP1-DT and MAP3K3 3’UTR, respectively.

Recent studies have reported that miR-188-5p is a tumour suppressor and is significantly downregulated in various cancers,
Fig. 6  ETV5 enhances HGSOC cell proliferation, migration and invasion through lncRNA CTBP1-DT.  

A, B Cells were transfected with indicated sh-Control, sh-ETV5-2, sh-ETV5-2 with CTBP1-DT and CTBP1-DT, respectively. CCK-8 and colony formation assays were used to determine the proliferation of SKOV3 or A2780. C Cells were transfected with indicated Control, ETV5, ETV5 with sh-CTBP1-DT and sh-CTBP1-DT, respectively. Proliferation of OV2008 was detected by CCK-8 and colony formation assays. D, E After transfected with sh-Control, sh-ETV5-2, sh-ETV5-2 with CTBP1-DT and CTBP1-DT, transwell migration and invasion assays were performed in SKOV3 and A2780, respectively. F After transfected with Control, ETV5, ETV5 with sh-CTBP1-DT and sh-CTBP1-DT, transwell migration and invasion assays were performed in OV2008, respectively. Data are presented as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
such as gastric [33], breast [34] and colorectal cancer [35]. In this study, miR-188-5p inhibitor promoted IncRNA CTBP1-DT expression in OV2008; however, miR-188-5p mimics inhibited IncRNA CTBP1-DT expression. Consequently, the expression of MAP3K3 was consistent with the change in IncRNA CTBP1-DT. Furthermore, miR-188-5p inhibitor upregulated the expression of IncRNA CTBP1-DT and MAP3K3, which could be significantly reversed by its mimics. These results suggest that IncRNA CTBP1-DT may act as a miR-188-5p sponge to protect MAP3K3 from degradation, thus increasing MAP3K3 expression in HGSOC.

However, the regulators involved in the abnormal expression of IncRNA CTBP1-DT in HGSOC cells remain unclear. Similar to protein-coding transcripts, the transcription of IncRNAs is subject to typical epigenetic-mediated and transcription factor-mediated regulation [36, 37]. Here, ETV5 showed the highest correlation with IncRNA CTBP1-DT based on data from JASPAR, an online bioinformatics software programme. The ETS family of transcription factors contributes to several physiological and pathological processes such as embryogenesis, wound healing and tumour progression [38]. In the present study, we demonstrated that overexpression of IncRNA CTBP1-DT in HGSOC cells could be activated when the transcription factor ETV5 binds to its promoter region. In addition, a clear decline in the proliferative, migratory and invasive capacity of A2780 and SKOV3 was observed when ETV5 was knocked down. This phenomenon was reversed by knockdown of ETV5 and overexpression of IncRNA CTBP1-DT. Moreover, ETV5 markedly promoted malignant cell behaviour in OV2008. This effect was abolished by the knockdown of the IncRNA CTBP1-DT. The effects of ETV5 on HGSOC cell proliferation, migration and invasion may partly be due to the IncRNA CTBP1-DT, which coincides with the functions of IncRNA CTBP1-DT. Finally, there was a high positive correlation between ETV5 and MAP3K3, which further proves that ETV5 regulates the expression of MAP3K3 by regulating IncRNA CTBP1-DT expression.

In our study, we have shown that IncRNA CTBP1-DT is regulated by the transcriptional factor ETV5, which is significantly upregulated in HGSOC, and can be used as a prognostic biomarker for HGSOC patients. It functions as a ceRNA that competitively binds miR-188-5p, upregulates MAP3K3 and promotes HGSOC cell proliferation, metastasis and invasion. These findings provide a new mechanism for understanding the development and progression of HGSOC, and IncRNA CTBP1-DT may be a potential candidate for the prevention and treatment of HGSOC.

MATERIALS AND METHODS

HGSOC patients and tissue specimens

A total of 87 HGSOC tissues and 35 normal fallopian tube tissues were obtained from HGSOC patients who underwent surgery at First Affiliated Hospital, School of Medicine, Shihezi University (Xinjiang, China) from 2005 to 2019. None of the patients received radiotherapy or chemotherapy before surgery. All tissue samples were immediately frozen in liquid nitrogen after resection from HGSOC patients and stored at −80°C. This study used human carcinoma tissues and was approved by the Committee for Ethical Review of Research involving Human Subjects of First Affiliated Hospital, School of Medicine, Shihezi University. Informed consent was obtained from all patients.

Cell lines and culture conditions

Human ovarian carcinoma cell lines (SKOV3, A2780, C13*, OV2008, HeyA8 and OVC4A33), oesophageal carcinoma cells (109), angiosarcoma cells (ISO) and clear cell renal carcinoma cells (786–0) were cultured in RPMI-1640 medium (GIBCO, Carlsbad, CA, USA) containing 10% foetal bovine serum (FBS; Biological Industries), 100 U/mL penicillin and 100 mg/mL streptomycin (Solarbio, Beijing, China) in humidified air at 37°C with 5% CO2. HEK-293T cells were cultured in Dulbecco’s Modified Eagle Medium (GIBCO) supplemented with 10% FBS, 100 U/mL penicillin and 100 mg/mL streptomycin in humidified air at 37°C with 5% CO2, SKOV3, A2780, HeyA8, ISO-109, 786–0, ISO and 293T cells were purchased from the Chinese Academy of Sciences Type Culture Collection (Shanghai, China). OV2008 and C13* cells were obtained from Prof. Benjamin K. Tsang (Ottawa Health Research Institute, Ottawa, Canada). OVC4A33 cells were obtained from Dr Gang Chen (Department of Gynecology and Obstetrics, Tongji Hospital of Huazhong University of Science and Technology).

Plasmid construction and transfection

For IncRNA CTBP1-DT or ETV5 overexpression, the full-length IncRNA CTBP1-DT or ETV5 cDNA was amplified and subcloned into pcDNA3.1. An empty vector was used as a negative control. The putative IncRNA CTBP1-DT promoter regions (−2000/0, −1200/0 and −300/0) were PCR-amplified from the genomic DNA and then inserted into the HindIII-Nhel sites upstream of the firefly lucerase in the pGL3-Basic vector (Promega, Madison, WI, USA). All constructs were named based on the location of the promoter fragments relative to the transcription start site (TSS). MAP3K3 and sh-MAP3K3 plasmids were provided by Dr Yang (Baylor College of Medicine, USA). All plasmids were isolated using an E.N.Z.A Eno-free Plasmid DNA Mini Kit II (OMEGA, D96950-01, USA). An hsa-miR-188-5p mimic was used instead of miR-188-5p, a chemically modified antisense oligonucleotide (antagomir AMQ-101) was used to inhibit miR-188-5p expression and a scrambled oligonucleotide (GenePharma) was used as a control. Cells were seeded in 6-well plates and cultured to 60–70% confluence before transfection. Lipofectamine® 2000 reagent (Life Technologies, USA) was used as the transfection medium according to the manufacturer’s protocol.

Bioinformatics methods

Potential IncRNA-binding sites of MAP3K3 were predicted by the TCGA database (https://genome-cancer.ucsc.edu/proj/site/hgHeatmap/). The Kaplan–Meier Plotter tool (http://kmplot.com/analysis/) was used to evaluate the association between MAP3K3 and the prognosis of OC patients. The IncRNA CTBP1-DT sequence was downloaded from the UCSC Genome Browser (http://genome.ucsc.edu/), from which the 2000-bp TSS upstream sequence was extracted. To identify putative transcription factors, the promoter sequence of IncRNA CTBP1-DT was submitted to the JASPAR programme (http://jaspar.genereg.net/).

RNA extraction and qRT-PCR analyses

Total RNA was extracted from the tissues and cultured cells using the miNeasy FFPE Kit and miNeasy Mini Kit (QIAGEN, Germany) in accordance with the manufacturer’s instructions. Approximately 1 μg of total RNA was reverse transcribed to cDNA (complementary DNA) using a miScript II RT kit (QIAGEN, Germany), and qPCR was performed using a miScript SYBR Green PCR kit (QIAGEN, Germany). Comparative quantification was performed using the 2−ΔΔCt method, with GAPDH as the endogenous control. Primer sequences used in PCR are listed in Supplementary Table 1.

Cell proliferation and colony formation assays

For the cell proliferation assay, 24 h after transfection, tumour cells were seeded into 96-well plates and cultured for 6 days. In each well, 10 μL of Cell Counting Kit-8 solution (Dojindo, Tokyo, Japan) was added daily. Cell viability was evaluated by measuring the absorbance at a wavelength of 450 nm. For the colony formation assay, tumour cells (500 cells per well) were seeded into 6-well plates 24 h after transfection. After 10–12 days of incubation, the cells were fixed in methanol and stained with 0.1% crystal violet. The colonies were counted using Quantity One software (Bio-Rad, Hercules, CA, USA). All experiments were performed three times, and the mean was calculated.

Cell migration and wound healing assays

Cells were seeded in the upper chamber of transwell plates (Corning, NY, USA) in a serum-free medium. FBS (10%) was added to the lower chamber of the transwell. Next, cells were transfected as described above for 48 h. For the invasion experiments, the upper chamber was covered with RPMI-1640 and Matrigel (BD Biosciences, San Jose, CA) mixture. Finally, cells on top of the chamber were removed with cotton swabs, while cells that went through the membrane (lower chamber) were stained with 0.1% crystal violet (Solarbio, Beijing, China), observed and counted under a microscope at 100× magnification.
Isolation of cytoplasmic and nuclear RNA
Cytoplasmic and nuclear RNAs of cells were extracted and purified using the Cytoplasmic and Nuclear RNA Purification Kit (Norgen) according to the manufacturer’s instructions.

Fluorescence in situ hybridisation (FISH)
Cells were fixed in 4% paraformaldehyde for 15 min at room temperature and then permeabilised with 0.3% Triton X-100 for 15 min at 4°C. Cells were incubated with digoxigenin (DIG)-labelled LncRNA CTBP1-DT/18S/U6 probe or Control-FISH probe mix for 4 h at 55°C and briefly washed with 2× saline-sodium citrate six times for 5 min. Horseradish peroxidase-conjugated anti-DIG secondary antibodies (Jackson, West Grove, PA, USA) were used to detect the signal, and nuclei were counterstained with DAPI. Images were obtained using an Olympus confocal laser scanning microscope.

Luciferase reporter assays
Human HEK 293T cells (2.0 × 10^6) grown in a 96-well plate were co-transfected with 150 ng of either empty vector or miR-188-5p, ETV5, 50 ng of firefly luciferase reporter comprising 3’UTR of MAP3K3, wild-type or mutant MAP3K3/LncRNA CTBP1-DT fragment and 2 ng of pRL-TK (Promega, Madison, WI, USA) using Lipofectamine 2000 reagent (Life Technologies, USA) to act as a negative control. Cells were harvested 48 h after transfection for luciferase assay using a luciferase assay kit (Promega, USA) according to the manufacturer’s protocol. Transfection was performed in triplicate.

Chromatin immunoprecipitation (ChIP)
ChIP assays were performed using a ChIP kit (CST, USA) following the manufacturer’s instructions. Briefly, cells were crosslinked with formaldehyde and sonicated to an average length of 0–2000 bp. Immunoprecipitation was conducted with an anti-ETVS antibody (orb69269, Bioryb, UK) or IgG control. The precipitated DNA was amplified by RT-PCR. Primer sequences used in ChIP are listed in Supplementary Table 1.

RNA-binding protein immunoprecipitation (RIP) assay
RIP assay A MagNA RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, USA) was used to determine the relationship between IncRNA CTBP1-DT and miR-188-5p or ETV5. Antibodies used for the RIP assay included anti-AGO2 and control IgG (Millipore, USA), and the coprecipitated RNAs were used for cDNA synthesis and evaluated by qRT-PCR. Primer sequences used in PCR are listed in Supplementary Table 1.

Western blot assay and antibodies
Cell protein lysates were separated by 10% SDS polyacrylamide gel electrophoresis, transferred to 0.45 μm polyvinylidene difluoride membrane (Solarbio, Beijing, China) and incubated with specific antibodies. Anticardiograms were quantified by densitometry (Quantity One software; Bio-Rad). β-actin antibody (1:1000, IE9A3, Zhongshan Biotechnology, Beijing, China) was used as a control. Anti-MAP3K3 (1:1000) was purchased from Abcam (ab40756, Cambridge, UK).

Tumour formation assay and tumour imaging in a nude mouse model
A total of 16 BALB/c nu/nu female mice of 4–6-week-old were divided into two groups (8 mice/group). SKOV3 cells (5 × 10^6 cells) were subcutaneously injected into the subcutaneous tissue of 16 BALB/c nu/nu female mice. After 36 days, the nude mice were anaesthetised for in vivo optical imaging by IVIS spectrum pre-clinical in vivo imaging system.

Statistical analysis
All the data of this experiment are the results of three independent repeated experiments. SPSS 22.0 software and GraphPad Prism 8.0 were used to analyse the data. Data are presented as the mean ± standard error of the mean for the experimental data conforming to the normal distribution, and t-test or one-way ANOVA was used to analyse the significance of differences between different groups. Median and quartile ranges are reported for non-normally distributed experimental data, and Wilcoxon rank sum test was used to analyse the significant differences between different groups. OS was evaluated by Kaplan–Meier survival curves and compared using the log-rank test. The classification data, such as age, FIGO stage, chemotherapy response and ascites, were described by frequency and percentage. The relationship between IncRNA CTBP1-DT and the clinicopathological features were compared by the χ² test. Univariate and multivariate Cox proportional hazard regression models were used to determine the effects of variables on survival. Inspection level: α = 0.05. *P < 0.05, **P < 0.01, ***P < 0.001. P < 0.05 was considered statistically significant.

DATA AVAILABILITY
The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.

REFERENCES
1. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68:284–96.
2. Siegel R, Miller K, Fuchs H, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.
3. Lheureux S, Gourney C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393:1240–53.
4. Hu Z, Artibani M, Aislaadi A, Wietek N, Morotti M, Shi T, et al. The repertoire of serous ovarian cancer non-genetic heterogeneity revealed by single-cell sequencing of normal fallopian tube epithelial cells. Cancer Cell. 2020;37:226–42, e7
5. Lawsonron K, Song F, Halezelt D, Kar S, Tynor J, Phelan C, et al. Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. Gynecologic Oncol. 2019;153:343–55.
6. Cabili M, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011;25:1915–27.
7. Geisler S, Coller J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol. 2013;14:699–712.
8. Xue X, Yang Y, Zhang A, Fong K, Kim J, Song B, et al. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene. 2016;35:2746–55.
9. Shi D, Zheng H, Zhou C, Peng J, Li D, Xu Y, et al. Low expression of novel IncRNA RP11–462C24.1 suggests a biomarker of poor prognosis in colorectal cancer. Med Oncol. 2014;31:313.
10. Xue C, Shao Y, Xia T, Yang Y, Dai J, Lui L, et al. IncRNA-AC130710 targeting by miR–129-5p is upregulated in gastric cancer and associates with poor prognosis. Tumour Biol. 2014;35:9701–6.
11. Cao Y, Xu R, Xu X, Zhou Y, Cui I, He X. Downregulation of IncRNA CASC2 by microRNA-21 increases the proliferation and migration of renal cell carcinoma cells. Mol Med Rep. 2016;14:1019–25.
12. Jiang L, Li Z, Wang R. Long non-coding RNAs in lung cancer: regulation patterns, biologic function and diagnosis implications (review). Int J Oncol. 2019;55:858–96.
13. Sassenberg M, Droop J, Schulz W, Dietrich D, Loick S, Wiek C, et al. Upregulation of the long non-coding RNA ASC9 as a biomarker for squamous cell carcinoma. BMC Cancer. 2019;19:1986.
14. Yang S, Shi F, Du Y, Wang Z, Feng Y, Song J, et al. Long non-coding RNA CTBP1–AS2 enhances cervical cancer progression via up-regulation of ZNF217 through sponging miR-3163. Cancer Cell Int. 2020;20:343.
15. Wang M, Zhao H. LncRNA CTBP1–AS2 promotes cell proliferation in hepatocellular carcinoma by regulating the miR-623/Cyclin D1 axis. Cancer Biother Radiopharm. 2020;35:765–70.
16. Cesana M, Caciarielli D, Legnini I, Santini T, Sthander O, Chinappi M, et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell. 2011;147:538–69.
17. Thomson D, Dinger M. Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet. 2016;17:272–83.
18. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi P. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011;146:353–8.
19. Tay Y, Rinn J, Pandolfi P. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505:344–52.
20. Liang H, Yu T, Han Y, Jiang H, Wang C, You T, et al. LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression. Mol Cancer. 2018;17:119.
21. Jia W, Dong Y, Tao L, Pang L, Ren Y, Liang W, et al. MAP3K3 overexpression is associated with poor survival in ovarian carcinoma. Hum Pathol. 2016;50:162–9.
22. Zhang Y, Wang S, Tao L, Pang L, Zou H, Liang W, et al. Overexpression of MAP3K3 promotes tumour growth through activation of the NF-kB signalling pathway in ovarian carcinoma. Sci Rep. 2019;9:8401.
23. Zhang J, Liu X, Li C, Wu X, Chen Y, Li W, et al. SNCG promotes the proliferation and metastasis of high-grade serous ovarian cancer via targeting the PI3K/AKT signaling pathway. J Exp Clin Cancer Res. 2020;39:79.
24. Si L, Chen J, Yang S, Liu Z, Chen Y, Peng M, et al. InCrcRNA HEIH accelerates cell proliferation and inhibits cell senescence by targeting miR-3619-5p/CTTNBP2 axis in ovarian cancer. Menopause. 2020;27:1302–14.
25. Zheng Z, Liu Y, Wang H, Pang W, Wang Y. LncRNA SNHG17 promotes proliferation and invasion of ovarian cancer cells through up-regulating FOXA1. Eur Rev Med Pharmacol Sci. 2020;24:2822–9.
26. Dong L, Cao X, Luo Y, Zhang G, Zhang D. A positive feedback loop of IncRNA DSCR8/miR-98-5p/STAT3/HIF-1α plays a role in the progression of ovarian cancer. Front Oncol. 2020;10:1713.
27. Liu J, Hu H, Liu Y, Li F, Zhang L, Liao Z. LncRNA HOTTIP promotes the proliferation and invasion of ovarian cancer cells by activating the MEK/ERK pathway. Mol Med Rep. 2020;22:6677–76.
28. Guo B, Yu L, Sun Y, Yao N, Ma L. Long non-coding RNA USP2-AS1 accelerates cell proliferation and migration in ovarian cancer by sponging miR-520d-3p and up-regulating KIAA1522. Cancer Manag Res. 2020;12:10541–50.
29. Dong S, Wang R, Wang H, Ding Q, Zhou X, Wang J, et al. HOXD-AS1 promotes the epithelial to mesenchymal transition of ovarian cancer cells by regulating miR-186-5p and PIK3R3. J Exp Clin Cancer Res. 2019;38:110.
30. Cui K, Zhu G. LncRNA CTBP1-AS2 regulates miR-216a/PTEN to suppress ovarian cancer cell proliferation. J Ovarian Res. 2020;13:84.
31. Louro R, Smirnova A, Verjovski-Almeida S. Long intronic noncoding RNA transcription: expression noise or expression choice? Genomics. 2009;93:291–48.
32. Chen L. Linking long noncoding RNA localization and function. Trends Biochemical Sci. 2016;41:761–72.
33. Peng Y, Shen X, Jiang H, Chen Z, Wu J, Zhu Y, et al. miR-188-5p suppresses gastric cancer cell proliferation and invasion via targeting ZFP91. Oncol Res. 2018;27:65–71.
34. Wang M, Zhang H, Yang F, Qiu R, Zhao X, Gong Z, et al. miR-188-5p suppresses cellular proliferation and migration via IL6ST: a potential noninvasive diagnostic biomarker for breast cancer. J Cell Physiol. 2020;235:4890–901.
35. Yan S, Yue Y, Wang J, Li W, Sun M, Gu C, et al. LINC00668 promotes tumorigenesis and progression through sponging miR-188-5p and regulating USP47 in colorectal cancer. Eur J Pharmacol. 2019;858:172464.
36. Chen J, Wu P, Xia R, Yang J, Hua X, Gu D, et al. STAT3-induced IncRNA HAGLROS overexpression contributes to the malignant progression of gastric cancer cells via mTOR signal-mediated inhibition of autophagy. Mol Cancer. 2018;17:6.
37. Huarte M, Guttman M, Feldser D, Garber M, Koziol M, Kozelmans-Broz D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell. 2010;142:409–19.
38. Sementchenko V, Watson D. Ets target genes: past, present and future. Onco-gene. 2000;19:6533–48.

AUTHOR CONTRIBUTIONS
WJ designed research studies. RF, HZ, WL and LT acquired data. PL analysed data. KC, LZ and SW conducted experiments. PL wrote the manuscript. Co-first authors PL, RF and KC share the first-author position. All authors read and approved the final paper.

FUNDING
This work was funded by the National Natural Science Foundation of China (Nos. 81960465, 82002741, 82060471), the high-level talent project of Shihezi University (Nos.RCZK2018C17, ZZZC202066A), the Youth Science and Technology Innovation Leading Talents Project of Corps (No. 2017CB004), the Xinjiang Production and Construction Corps Key Areas Innovation Team Project (No. 2018CB002) and the Non-profit Central Research Institute Fund of Chinese Academy of Medical Science (2020-PT330-003). No funding or other benefits related to the subject of this article were received from any commercial entity.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE
This study used human cancer tissues and was approved by the Committee for Ethical Review of Research involving Human Subjects of First Affiliated Hospital, School of Medicine, Shihezi University. The study was performed in accordance with the Declaration of Helsinki.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41419-021-04256-9.

Correspondence and requests for materials should be addressed to Wei Jia.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021